“Meet-URO Score Validation in Real-World Patients With Metastatic Renal Cell Carcinoma Receiving First-Line Pembrolizumab Plus Axitinib: A Subanalysis of the Prospective ProPAXI Study”. Journal of Kidney Cancer, vol. 12, no. 4, Oct. 2025, pp. 7-18, https://doi.org/10.15586/jkcvhl.v12i4.403.